BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm Bill

Oct 19 2017
BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and unconditionally allow renewable chemical standalone manufacturing facilities” to receive Section 9003 Program loan guarantees without requiring production of advanced biofuels.

BIO Applauds Senate Introduction of Renewable Chemicals Tax Credit

Oct 19 2017
BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short-term tax credit for production of qualifying renewable chemicals or investment in production facilities.

BIO Investor Forum Concludes

Oct 18 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase over last year. The event was attended by more than 1,000 representatives of private and early stage biotech companies, leading investment firms, research organizations and others who came together to foster the development of new medical treatments and to grow the industry’s pipeline. 

Hill Leaders Urge Support for Reg System that Supports Ag Innovation

Oct 17 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders”  Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a letter urging for a “consistent, science-based, risk-proportionate regulatory system” for agricultural biotechnology.

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

Oct 9 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided government intrusion.

BIO Congratulates SAB Biotherapeutics on Pharm Groundbreaking

Oct 5 2017
Sioux Falls, S.D. 80-acre biological pharm is first-of-its kind   Washington, D.C. (October 5, 2017) – Sioux Falls, S.D.-based SAB Biotherapeutics, Inc. (SAB), celebrated construction of their 80-acre biopharmaceutical production pharm operation with a groundbreaking ceremony today in Lincoln County. 

Sixth Annual BIO Patient and Health Advocacy Summit Concludes Today

Oct 3 2017
The 2017 Patient and Health Advocacy Summit wrapped up today, having offered the nearly 240 patient groups, companies and organizations new ways to connect, strategize, learn and partner.  For the past six years, the BIO Patient and Health Advocacy Summit has brought together a diverse group of organizations including patient advocacy, health care providers, academia, government, think tanks, professional societies and the biotechnology industry to focus on bringing the patients’ voice to the drug development process. 

BIO to Offer Complimentary Access to One-on-One Partnering™ During J.P. Morgan Healthcare Conference (“JPM Week”)

Sep 28 2017
BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018  

BIO Statement on California’s Drug Price Reporting & Transparency Bill

Sep 13 2017
California Senate Bill 17 is bad for patient and does not deliver on its purported promises

FDA Commissioner, Dr. Scott Gottlieb, to Address BIO Patient and Health Advocacy Summit

Sep 5 2017
The head of the United States Food and Drug Administration, Dr. Scott Gottlieb, will be the keynote speaker at the BIO Patient and Health Advocacy Summit, October 2-3 at the Mayflower Hotel in Washington, DC. The annual event brings together attendees representing patient advocacy groups, health care providers, academia, government, think tanks, professional societies and the biotechnology industry and provides a forum for lively discussions on timely health policy issues and best practices.